… In our experiments, CFU-S and CFU-T activities were present together in a single
population, the Thy-l'"Lin"'gSca-l' subset.*" Within reasonable error, it turned out that the Thy-…

… ’s lymphoma compared with non-Hodgkin’s lymphoma or multiple myeloma 8 ) or the
type of prior treatments given and chemotherapeutic agents received, 15 as can the infusion …

… of pathogenic cell types for Crohn’s disease, multiple sclerosis, and … Although Crohn’s
pathology has classically been associated … any prior knowledge about Crohn’s disease pathology. …

A review of the published literature, supplemented with a recent analysis of Fred Hutchinson
data, has been undertaken to investigate the association of infused CD34 cell dose with …

… The eligibility criteria for this study did not exclude any patient based on the absolute
lymphocyte count or on a predetermined measurement of the ability of the patient’s T cells to …

Background In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood
cells mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating factor) …

… , results of therapy in refractory non-Hodgkin’s lymphoma (NHL) have been less impressive
(… %, depending on the status of the patient’s disease at the time the T cells were collected (15)…

Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …

Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–modified
T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had …

MicroRNAs (miRNAs) are a recently identified class of epigenetic elements consisting of
small noncoding RNAs that bind to the 3′ untranslated region of mRNAs and down-regulate …